ARCH Venture Fund XIII Makes Substantial $12.5M Open Market Purchase, Part of Coordinated $25M Insider Buy

summarizeSummary

ARCH Venture Fund XIII and its affiliates, all 10% owners, made a substantial $12.5 million open market purchase of Lyell Immunopharma shares, part of a larger, coordinated $25 million insider buying effort by the ARCH group.

check_boxKey Events

• Significant Insider Purchase

  ARCH Venture Fund XIII, L.P. and its affiliated 10% owners acquired 488,090 shares of Lyell Immunopharma common stock in an open market purchase valued at $12,499,985 on March 6, 2026.

• Substantial Investment Relative to Market Cap

  This single transaction represents approximately 2.3% of Lyell Immunopharma's current market capitalization, indicating a high-conviction investment.

• Coordinated Institutional Buying

  This purchase is part of a larger, coordinated effort by the ARCH Venture group, with another affiliated fund (ARCH Venture Fund IX) reporting a similar $12.5 million purchase on the same day, bringing the total insider buying from this group to approximately $25 million.

• Strong Accumulation Signal

  The combined insider buying from the ARCH group on this day amounts to roughly 4.6% of the company's market cap, reinforcing a strong accumulation trend by key institutional investors.

auto_awesomeAnalysis

This Form 4 reports a significant open market purchase of Lyell Immunopharma shares by ARCH Venture Fund XIII, L.P. and its affiliated 10% owners, totaling nearly $12.5 million. This transaction, representing over 2.3% of the company's market capitalization, signals strong conviction from a major institutional investor. Notably, this filing explicitly states it is one of two reports related to a joint transaction, with another ARCH Venture Fund (ARCH Venture Fund IX) also reporting a similar $12.5 million purchase on the same day. The combined $25 million investment from the ARCH group, representing approximately 4.6% of the company's market cap, indicates a highly bullish stance and a substantial vote of confidence in Lyell Immunopharma's future.